



## Product Information

**Product ID** A046189

**CAS No.** 783355-60-2

**Chemical Name**

**Synonym** PCI-24781, CRA-024781, DRA-24781

**Formula** C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>

**Formula Wt.** 397.16

**Melting Point**


**Purity** ≥98%

**Solubility**

**Store Temp** -20°C

**Ship Temp** Ambient

**Description** Abexinostat is an inhibitor of histone deacetylase (HDAC). While it primarily targets HDAC1, it also shows activity against HDAC2, 3, 6, 8, and 10. Abexinostat has shown synergistic effect with bortezomib in lymphoma cells, inducing caspase-dependent apoptosis in vitro. It has exhibited efficacy when used in combination with doxorubicin against metastatic sarcoma.



## Pricing and Availability

**Bulk quantities available upon request**

Product ID	Size	List Price
A046189	5 mg	\$110.00
A046189	25 mg	\$425.00
A046189	100 mg	\$1200.00

**References** Bhalla S., Balasubramanian S., et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 15(10):3354-65 (2009). PMID: 19417023.

Choy E., Flamand Y., et al. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 121(8):1223-30 (2015). PMID: 25536954.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.